Morgan Stanley Lowers Personalis (PSNL) Price Target to $10

Personalis, Inc. (NASDAQ:PSNL) is 1 of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

On March 5, 2026, Personalis, Inc. (NASDAQ:PSNL) saw its terms people from Morgan Stanley lowered from $11 to $10. The firm’s expert maintained an Equal Weight standing connected the banal aft updating its estimates to bespeak an accrued 2026 nett nonaccomplishment guidance and higher projected semipermanent operating expenses.

In different development, connected March 12, 2026, Personalis, Inc. (NASDAQ:PSNL) announced the work of the PREDICT-DNA survey successful the Journal of Clinical Oncology. The survey highlighted the effectiveness of its NeXT Personal assay successful monitoring bosom cancer. It tracks up to 1,800 tumor-specific variants to supply precise risk-stratification. Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D, Personalis, Inc. (NASDAQ:PSNL), gave the pursuing statement:

The results of this survey suggest that an ultrasensitive ctDNA assay similar NeXT Personal could assistance patients amended recognize their effect to neoadjuvant therapy, with the imaginable to assistance pass the request for further therapy.

Founded successful 2011, Personalis, Inc. (NASDAQ:PSNL) is simply a crab genomics person specializing successful ultrasensitive liquid biopsy tests for minimal residual illness (MRD). Its office is successful California.

While we admit the imaginable of PSNL arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest successful During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey connected Google News.